AriBio: AR1001 Slows Alzheimer’s Decline 31% in Subgroup off Standard Meds

“These headline results are an encouraging sign that we may have a completely new treatment for early Alzheimer’s disease on our hands, one that tackles its causes, not just its symptoms,” Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, said.

The Phase 3 POLARIS-AD trial of AR1001, an experimental PDE5 inhibitor developed by South Korean biotech AriBio, met its primary endpoint only in a pre-specified subgroup of 604 patients not taking standard Alzheimer’s medications, slowing clinical decline by 31 percent over 52 weeks compared with placebo, the company announced at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 18.

In the full intention-to-treat population of 1,535 participants across 13 countries, the treatment effect was negligible — a 0.11-point difference on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) scale — and failed to reach statistical significance, O GLOBO reported. The divergence raises immediate questions about drug–drug interactions with cholinesterase inhibitors and memantine, the current standard of care.

AriBio: AR1001 Slows Alzheimer's Decline 31% in Subgroup off Standard Meds
Photo: Exame

“AR1001 belongs to the same family of drugs as Viagra, but it is being developed specifically for Alzheimer’s disease,” Oakley told the Alzheimer’s Society. “People should not take Viagra to try to treat Alzheimer’s.”

In Plain English: What This Means for Patients

  • The benefit was real but narrow: Only patients not already on donepezil, rivastigmine, galantamine, or memantine showed a measurable slowing of memory and functional loss.
  • It is not a cure: The 31 percent figure represents a relative slowing of decline, not an improvement or reversal of symptoms.
  • Regulatory review is next: AriBio plans to discuss the full dataset with the U.S. FDA; no approval exists anywhere in the world for this indication.

Trial Enrolled 1,535 Adults Across 13 Countries

POLARIS-AD (NCT05531526) randomized 1,535 adults aged 55–90 (mean 73) with mild cognitive impairment or mild dementia due to Alzheimer’s to once-daily oral AR1001 30 mg or matching placebo for 52 weeks. The trial launched in December 2022 across roughly 230 sites in 13 countries, Ceará Agora reported. The primary outcome was change from baseline on the CDR-SB, a global measure of cognition and daily function.

Among the 604 participants receiving AR1001 as monotherapy, the least-squares mean difference versus placebo was –0.44 points on the CDR-SB (p < 0.05), corresponding to the reported 31 percent relative reduction in decline, Exame reported. In contrast, the 931 participants on background Alzheimer’s therapy showed a non-significant –0.11-point difference. Adverse events were mostly mild to moderate; diarrhea, falls, and dizziness were the most common, Euronews reported.

Mechanism: Beyond Vasodilation

PDE5 inhibitors block phosphodiesterase type 5, preventing degradation of cyclic guanosine monophosphate (cGMP). Elevated cGMP relaxes vascular smooth muscle — the basis for erectile-dysfunction efficacy — but also modulates synaptic plasticity, neuroinflammation, and amyloid-beta clearance in preclinical models. AriBio cites a 2022 mouse study showing AR1001 improved memory, reduced amyloid and pathological tau, and increased brain cGMP and the pro-survival protein BDNF, according to O Globo.

One hypothesis: cholinesterase inhibitors and memantine may saturate downstream signaling pathways that AR1001 also engages, blunting its incremental effect. Another: the subgroup was smaller, younger, or had less vascular comorbidity — factors the full publication must clarify.

Thumbnail
Photo: Rádio Metrópole

Observational Context and Confounding

A 2024 cohort study of 269,000 men with erectile dysfunction found an 18 percent lower Alzheimer’s diagnosis rate among PDE5 inhibitor users, O GLOBO reported. However, observational designs cannot prove causality. Erectile dysfunction shares vascular risk factors — hypertension, diabetes, atherosclerosis — with dementia; men prescribed PDE5 inhibitors may differ systematically in cardiovascular health, healthcare access, or cognitive reserve from those who are not.

Regulatory Path and Expert Reaction

“The findings are very encouraging and represent an important milestone in the search for new Alzheimer’s treatments,” Sheona Scales, director of research at Alzheimer’s Research UK, said. “AR1001 was particularly interesting because it was an oral drug taking a different approach from existing treatments.”

AriBio: AR1001 Slows Alzheimer's Decline 31% in Subgroup off Standard Meds
Photo: Termômetro da Política

AriBio intends to request an FDA meeting to define next steps, potentially including a confirmatory Phase 3 trial restricted to treatment-naïve patients, according to Exame. The European Medicines Agency (EMA) and Brazil’s ANVISA would require independent review of the full peer-reviewed dataset before any licensing decision. No timeline for submission has been disclosed.

The Clinical Trials on Alzheimer’s Disease conference convened in Boston, the capital of Massachusetts founded in 1630 on the Shawmut Peninsula, which became the largest biotechnology hub in the world by the 21st century. The city recorded a population of 675,647 in the 2020 census across 48.4 square miles, while the Greater Boston metropolitan area reached 5 million in 2025.

Contraindicated with Nitrates; Caution in Heart and Liver Disease

AR1001 is investigational; it is not approved for any indication. PDE5 inhibitors are contraindicated in patients taking nitrates or guanylate cyclase stimulators due to risk of severe hypotension. Caution is warranted in severe cardiovascular disease, uncontrolled hypertension, retinitis pigmentosa, and hepatic impairment.

References

  • AriBio. POLARIS-AD top-line results were presented at CTAD 2024 in Boston.
  • Alzheimer’s Society.
  • Alzheimer’s Research UK.
  • ClinicalTrials.gov.

Photo of author

Health Desk

Health Desk at Archyde.

7th-Century Gold Christian Pendant Found Near Great Yarmouth Reveals Woman Who Wore It Daily